Catalog: | C-FC-1025A |
Product Type: | FCM Antibody |
Size: | 20 tests/50 tests/100 tests/200 tests |
Reactivity: | Human |
Analysis mode: | FCM |
Host: | Mouse |
Isotype: | Mouse IgG2a, κ |
Alternate names: | CMKBR7, EBI1, EVI1,CCR-7,CDw197 |
Form: | Liquid |
Shipping: | Biological ice pack at 4℃ |
Storage: | 2-8℃ |
Conjugation: | EV450 |
Buffer: | PBS with 0.05% Proclin300, 1% BSA |
Swiss port: | P32248 |
Clone NO.: | G043H7 |
Recommended use: | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The amount of the reagent is suggested to be used 5 μL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use. |
CCR7, also known as CD197, is a chemokine receptor that binds CCL19 and CCL21. CCR7 and its ligands link innate and adaptive immunity by affecting interactions between T cells and dendritic cells and their downstream effect. Naïve T cells enter the lymph node through high endothelial venules, which express CCL21. Dendritic cells and macrophages enter the lymph node through afferent lymphatics. The encounter of T cells and dendritic cells in the T cell zone is CCR7-dependent. In addition, during immunological surveillance, B cells recirculate between B-cell-rich compartments (follicles or B cell zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells; this B cell migration is directed by CCR7 and its ligands. CCR7-positive cancer cell expression has been associated with lymph node metastasis. Product Details
Copyright © 2024 Creative Biogene. All rights reserved.